Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE... by Zhou, Qing, Prof, Chen, Ming, Prof, Jiang, Ou, Prof, Pan, Yi, Prof, Hu, Desheng, Prof, Lin, Qin, PhD, Wu, Gang, Prof, Cui, Jiuwei, Prof, Chang, Jianhua, Prof, Cheng, Yufeng, Prof, Huang, Cheng, Prof, Liu, Anwen, Prof, Yang, Nong, Prof, Gong, Youling, Prof, Zhu, Chuan, Prof, Ma, Zhiyong, Prof, Fang, Jian, Prof, Chen, Gongyan, Prof, Zhao, Jun, MD, Shi, Anhui, MD, Lin, Yingcheng, Prof, Li, Guanghui, MD, Liu, Yunpeng, Prof, Wang, Dong, Prof, Wu, Rong, Prof, Xu, Xinhua, Prof, Shi, Jianhua, Prof, Liu, Zhihua, MD, Cui, Na, PhD, Wang, Jingru, PhD, Wang, Qiang, MM, Zhang, Ran, MSc, Yang, Jason, MD, Wu, Yi-Long, Prof

Get full text

Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibit... by Lu, Shun, Prof, Wu, Lin, Prof, Jian, Hong, MD, Chen, Ying, Prof, Wang, Qiming, MD, Fang, Jian, Prof, Wang, Ziping, MD, Hu, Yanping, Prof, Sun, Meili, MD, Han, Liang, MD, Miao, Liyun, Prof, Ding, Cuimin, MD, Cui, Jiuwei, Prof, Li, Baolan, Prof, Pan, Yueyin, Prof, Li, Xingya, MD, Ye, Feng, MD, Liu, Anwen, Prof, Wang, Ke, MD, Cang, Shundong, MD, Zhou, Hui, MD, Sun, Xing, MD, Ferry, David, MD, Lin, Yong, MD, Wang, Shuyan, MD, Zhang, Wen, MD, Zhang, Chengli, MD

Get full text